Praxis Precision Medicines announced the presentation of a poster and platform talk showcasing its Phase 3 clinical program evaluating ulixacaltamide for adults with essential tremor at the Movement Disorders Society, MDS, 2024 International Congress taking place in Philadelphia, Pennsylvania, September 27 – October 1, 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision price target raised to $151 from $145 at Needham
- Praxis Precision price target raised to $143 from $134 at Oppenheimer
- Praxis Precision Medicines’ Promising EMBOLD Study Outcomes
- Praxis announces results from EMBOLD study in SCN2A 8A for epilepsies
- Praxis Precision management to meet virtually with Piper Sandler